# Adjuvant Comparison and Characterization (HIV)

> **NIH NIH N01** · STANFORD UNIVERSITY · 2023 · $1,780,989

## Abstract

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms. A major challenge for HIV vaccine development is learning how to induce robust and durable antibody responses that protect against mucosal infection. A critical step on the path to overcoming this challenge are developing adjuvants that appropriately stimulate robust and durable immune responses. The goal of this project is to assess the impact of 3 different adjuvants on enhancing the magnitude and durability of neutralizing antibody responses against HIV Env.

## Key facts

- **NIH application ID:** 10834856
- **Project number:** 75N93022C00052-P00001-9999-2
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** BALI PULENDRAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1,780,989
- **Award type:** —
- **Project period:** 2022-09-01 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10834856

## Citation

> US National Institutes of Health, RePORTER application 10834856, Adjuvant Comparison and Characterization (HIV) (75N93022C00052-P00001-9999-2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10834856. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*